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Abstract
Background: Predominantly, magnetic resonance imaging (MRI) studies in animal models of Parkinson’s disease
(PD) have focused on alterations in T2 water
1H relaxation or
1H MR spectroscopy (MRS), whilst potential
morphological changes and their relationship to histological or behavioural outcomes have not been appropriately
addressed. Therefore, in this study we have utilised MRI to scan in vivo brains from rodents bearing a nigrostriatal
lesion induced by intranigral injection of the proteasome inhibitor lactacystin.
Results: Lactacystin induced parkinsonian-like behaviour, characterised by impaired contralateral forelimb grip
strength and increased contralateral circling in response to apomorphine. T2-weighted MRI, 3-weeks post-lesion,
revealed significant morphological changes in PD-relevant brain areas, including the striatum and ventral midbrain
in addition to a decrease in T2 water
1H relaxation in the substantia nigra (SN), but not the striatum. Post-mortem
histological analyses revealed extensive dopaminergic neuronal degeneration and a-synuclein aggregation in the
SN. However, extensive neuronal loss could also be observed in extra-nigral areas, suggesting non-specific toxicity
of lactacystin. Iron accumulation could also be observed throughout the midbrain reflecting changes in T2.
Importantly, morphological, but not T2 relaxivity changes, were significantly associated with both behavioural and
histological outcomes in this model.
Conclusions: A pattern of morphological changes in lactacystin-lesioned animals has been identified, as well as
alterations in nigral T2 relaxivity. The significant relationship of morphological changes with behavioural and
histological outcomes in this model raises the possibility that these may be useful non-invasive surrogate markers
of nigrostriatal degeneration in vivo.
Background
Parkinson’s disease (PD) is a progressive neurodegenera-
tive movement disorder characterised by a selective vul-
nerability and degeneration of dopaminergic (DA)
neurons in the substantia nigra pars compacta (SNc) [1].
This is accompanied by formation of eosinophilic cyto-
plasmic inclusions in remaining neurons, termed Lewy
bodies (LB), composed primarily of fibrillar aggregates
of a-synuclein [2].
Degeneration of DA neurons in the SNc results in sig-
nificant depletion of striatal dopamine levels, which can
be readily visualised in PD patients using Positron
Emission Tomography (PET) in combination with speci-
fic radiotracers, such as 18-fluorodopa (
18F-DOPA) [3].
However, whilst there is abundant PET data for PD, the
results of magnetic resonance imaging (MRI)-morpho-
metric studies regarding the basal ganglia (BG) in PD
patients are still relatively scarce and inconsistent [4].
Indeed, brain atrophy is not routinely ascribed to
human idiopathic PD (iPD), particularly in cognitively
intact patients [5]. In early-stage iPD, both normal [6,7]
and partial reductions [8-10] in grey matter volume
(GMV) of the BG have been reported [4]. Similarly,
voxel-based morphometry (VBM) studies have reported
significant morphological changes, including atrophy of
the head of the left caudate nucleus and cortical changes
in both early and advanced iPD, which correlated
robustly with clinical symptoms [4,11]. Furthermore,
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tricles (LV) has been reported, which also correlated
robustly with patient disability scores on the Unified
Parkinson’s Disease Rating Scale (UPDRS) [12]. Impor-
tantly, patterns of morphometric change which can be
readily detected by MRI are already utilised clinically to
aid differential diagnosis of iPD from other forms of
parkinsonism, including the a-synucleinopathy multiple
system atrophy (MSA) and the tauopathy progressive
supranuclear palsy (PSP) [13,14].
In addition, it has been widely reported that T2 water
proton relaxivity rates are decreased in pathologically
relevant areas in iPD patients, including the SNc and
putamen, which has been ascribed to regional iron accu-
mulation [15-18]. Interestingly, a significant relationship
between T2 relaxivity, iron accumulation and clinical
symptoms has been described. Alterations in T2 relaxiv-
ity may therefore represent a surrogate marker for PD
progression, although only cross-sectional studies have
been performed to date [19,20]. By contrast, the possibi-
l i t yt h a tm o r p h o m e t r i cc h a nges, or a combination of
this with alterations in T2 relaxation time may be used
to non-invasively monitor disease progression in PD
remains unclear [21].
Crucial to a more mechanistic understanding of
pathology and the evaluation of novel treatments for PD
are animal models that reflect important aspects of the
clinical manifestation of the disease. Foremost of all,
rodent toxin-based models of PD, although subject to
limitations, have provided useful insights into the patho-
physiology of iPD [22]. Combining such animal models
with non-invasive imaging, such as MRI, offers a power-
ful tool with which to investigate potential dynamic
morphological changes due to degeneration of the
nigrostriatal system, which may lead to identification of
surrogate markers of disease progression [23,24]. Impor-
tantly, detailed anatomical or relaxivity information can
be correlated directly with behavioural phenotypes, rais-
ing the possibility that MRI could provide non-invasive
surrogate markers predictive of the degree of functional
impairment in individual animals [25].
Previous studies have elegantly demonstrated the
application of MRI to animal models of PD [26-31]. Pri-
marily however, these studies have focused on altera-
tions in T2 relaxation or
1H MR spectroscopy (MRS)
and more recently diffusion tensor imaging (DTI) [32]
and manganese enhanced MRI (MEMRI) [33]. In con-
trast, potential morphological changes and their rela-
tionship to histological or behavioural outcomes have
not been appropriately addressed. Therefore, in this
s t u d yw eh a v eu t i l i s e dM R It os c a nin vivo brains from
rodents bearing a nigrostriatal lesion induced by an
intranigral injection of the proteasome inhibitor lacta-
cystin. This relatively recently developed model has
been suggested to be a novel, pathologically relevant
model of PD [34-36], which has already been used with
some success in neuroprotection studies [35-38]. Our
primary aim in this study was to investigate whether
morphological and T2 relaxation times are altered in
PD-relevant brain areas in this new experimental model
of PD and to determine how these are related to beha-
vioural and histological outcomes.
Results
Behavioural testing
Lactacystin-lesioned animals, but not controls, initially
developed gross neurological deficits progressively, as
shown by a gradual worsening in neurological score
(Figure 1A). Lactacystin-lesioned animals consistently
showed deficits in spontaneous motility, which may be a
reflection of developing bradykinesia in these animals.
Lesioned animals also demonstrated clear deficits in the
horizontal bar, grasping reflex and placing reaction tests,
suggesting defects in skilled forelimb use. Lesioned ani-
mals showed only moderate deficits in the cage top test
and did not show any deficits in righting reflex or visual
placement test (Figure 1B). Consistent with the initial
progressive increase in global neurological score
between 3 and 7 days, the percentage of lactacystin-
lesioned animals that displayed deficits in these tests
increased in this period (Figure 1B). Modest further
increases in the percentage of animals displaying these
deficits were observed between days 7 to 21 post-lesion
(Figure 1B). However, this likely reflects inter-animal
variation in lesion size and not progressive lesion devel-
opment, as global neurological scores remain static (Fig-
ure 1A,B). Qualitatively, lactacystin-lesioned animals,
but not controls, also developed ipsiversive postural def-
icits and demonstrated spontaneous circling behaviour
ipsilateral to the lesioned hemisphere. Importantly, neu-
rological scores became static by 7 days post-lesion, and
did not increase further until sacrifice 3 weeks post-
lesion (Figure 1A).
To determine if lactacystin-lesioning affects forelimb
use, performance was assessed in the grip strength mea-
sure (GSM) test. Baseline measures of grip strength
were established prior to surgery with no significant dif-
ference in average grip force observed for either fore-
limb in either group (Figure 1C,D). No significant
deficits in grip strength between the contralateral and
ipsilateral forelimbs were observed in saline-injected
controls (Figure 1C). By contrast, 3-weeks post-surgery,
lactacystin-lesioned animals displayed a significant
decrease in the grip strength of the contralateral com-
pared to the ipsilateral forelimb (p < 0.001; Figure 1D).
No significant differences in the grip strength of the
ipsilateral limb were observed between lactacystin-
lesioned animals and controls at any time-point (Figure
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Page 2 of 18Figure 1 Assessment of neurological and behavioural deficits. (A) Neurological scoring (B) Percentage of lactacystin-lesioned animals that
are impaired in each of the neurological score tests at days 3, 7 and 21. (C) No significant reduction in forelimb grip strength was observed in
saline-injected controls. By contrast in lactacystin-lesioned animals (D) forelimb grip strength was significantly reduced in the contralateral
forelimb at 1 and 3 weeks post-lesion. Data shown are mean forelimb grip force (g) ± SEM *p < 0.01 saline vs. lactacystin. (C) Lactacystin-
lesioned animals displayed significantly increased rotational asymmetry in response to apomorphine challenge (0.1 mg/kg s.c.), Data shown are
mean area under curve (AUC) ± SEM ***p < 0.001 saline vs. lactacystin.
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tin-lesioned animals, but not saline controls, displayed
significantly increased net contraversive rotations follow-
ing an apomorphine challenge (p < 0.001, Figure 1E, F).
Lactacystin-lesioned animals displayed an average net
contraversive turns of >5 turns/min. This activity
increased steadily after 5 min and was maintained for
approximately 35 minutes, at which point locomotor
activity decreased back to baseline (Figure 1E). No spon-
taneous recovery of either neurological score or beha-
viour was observed during the 3 weeks of observation in
lactacystin-lesioned animals.
Brain regional volumes
Sample ROI used to obtain volumetric data are shown
in Figure 2A and the anatomical criteria used to define
individual brain structures are shown in Table 1. There
was a significant reduction in whole brain volume
(WBV) when comparing lactacystin-lesioned animals
and saline controls (1436 ± 18 vs. 1375 ± 11 mm
3; p <
0.05; Figure 2B). Measurements of individual brain
structures revealed numerous regional volume changes
in lactacystin-lesioned animals, but not saline controls.
Indeed, the ipsilateral striatum (STR) was found to be
significantly smaller relative to the non-injected contral-
ateral hemisphere in lactacystin-lesioned animals (20.04
± 0.93 vs. 24.93 ± 0.40 mm
3; p < 0.001; Figure 2C) and
the ipsilateral hemisphere of saline controls (20.04 ±
0.40 vs. 26.70 ± 0.79 mm
3; p < 0.001; Figure 2C). In
addition, the ipsilateral ventral midbrain (VM) was strik-
ingly deformed with a concomitant increase in the sur-
rounding cerebrospinal fluid (CSF) space. Quantitative
measurement revealed the ipsilateral VM to be signifi-
cantly smaller in lesioned animals compared to both the
non-injected contralateral hemisphere (38.03 ± 0.69 vs.
30.61 ± 0.66 mm
3; p < 0.001; Figure 2D) and the ipsilat-
eral hemisphere of saline control animals (35.51 ± 0.39
vs. 30.61 ± 0.66 mm
3; p < 0.001; Figure 2D).
Notably, the ipsilateral lateral ventricles (LV) were sig-
nificantly enlarged in lactacystin-lesioned animals
compared to both the non-injected contralateral hemi-
sphere (14.80 ± 2.30 vs. 9.02 ± 1.38 mm
3; p <0 . 0 1 ;F i g -
ure 2E) and the ipsilateral hemisphere of control
animals (14.98 ± 2.30 vs. 5.46 ± 0.29 mm
3; p < 0.01; Fig-
ure 2E). The contralateral LV in lactacystin lesioned ani-
mals was also significantly enlarged compared to saline
controls (9.02 ± 1.38 vs. 5.92 ± 0.36 mm
3; p < 0.05; Fig-
ure 2E).
No significant volume changes were observed in either
the absolute volume of the cerebellum (CB) (Figure 2F)
or for the hippocampal formation (HF) in either hemi-
sphere, when comparing saline and lactacystin-injected
animals (Figure 2F). These data are illustrated in repre-
sentative MR images in Figure 3A, where clear hypertro-
phy of the LV can be observed (Figure 3A) as well as
the striking deformation of the ipsilateral VM and corre-
sponding increase in CSF space (Figure 3B). With the
exception of the contralateral LV, no significant differ-
ences were observed for any brain region when compar-
ing the contralateral hemisphere of saline and
lactacystin-injected animals.
T2 signal intensity measurements
In lactacystin-lesioned animals, but not saline controls,
visual inspection of T2W images revealed no visible
areas of T2 signal change in the striatum in either hemi-
sphere between saline and lactacystin-lesioned animals
(Figure 3A). In contrast, areas of T2 hypointensity could
be clearly observed in the VM, particularly in an area
approximate to the location of the SN (Figure 3B).
Notably, however, areas of T2 hypointensity were also
observed in extra nigral regions throughout the ipsilat-
eral VM (Figure 3B). These data are supported by quan-
titative ROI-based T2 measurements, which revealed no
significant alterations in striatal T2 between hemispheres
in either lactacystin-lesioned animals or saline controls
(Figure 4A, B). By contrast, a moderate, but significant,
decrease in T2 relaxivity was observed in the ipsilateral
ventral midbrain and SN of lactacystin-lesioned animals,
relative to the non-injected contralateral hemisphere
and the ipsilateral SN of saline-injected controls (Figure
4C-F).
Post-mortem histology
To validate the origin of MRI signal changes and to
examine how these are associated with nigrostriatal
pathology, post-mortem immunohistological analyses
were performed on the nigrostriatal system. Unbiased
stereology cell counts revealed that intranigral injection
of lactacystin resulted in an 81.4 ± 1.1% reduction of
TH-positive (+) cells in the ipsilateral substantia nigra
pars compacta (SNc) compared to the intact contralat-
eral hemisphere (10,030 ± 214 vs. 1861 ± 219; p <
0.001; Figure 5A). This was mirrored by an 82.2 ± 2.0%
reduction in NeuN-positive (+) cells (10,380 ± 934 vs.
1825 ± 236; p <0 . 0 0 1 ;F i g u r e5 B ) ,s t r o n g l ys u g g e s t i n g
Table 1 Anatomical criteria for volume measurements.
Brain region Anatomical criteria for measurement
Whole Brain Base of the olfactory bulb to last slice containing cortex
Lateral
ventricles
Defined from brain tissue by intense contrast of CSF
Corpus
striatum
Defined with reference to corpus callosum, external
capsule, anterior comissure and lateral ventricles
Midbrain Defined with reference to dorsal hippocampal
formation
Hippocampus Defined with reference to corpus callosum and external
capsule
Cerebellum Defined with reference to 4
th ventricle and brainstem
as a guide
Abbreviations: AC = anterior commissure, CC = corpus callosum, EC = external
capsule
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tion of TH expression in atrophic neurons. No signifi-
cant differences were observed in either TH+ or NeuN+
cell counts between the contralateral and ipsilateral
hemispheres in saline-injected controls or between the
contralateral hemispheres in lactacystin-lesioned animals
and saline controls (Figure 5A, B). Notably however, the
pars reticulata of the SN (SNr) and the VTA were not
free from the direct toxicity of lactacystin. Indeed, quali-
tatively, extensive loss of both TH+ and NeuN+ cells
was observed in these regions when compared to saline
controls (Figure 5C, D). Microscopic analysis of extra-
nigral nuclei in the ipsilateral VM revealed additional
areas of neuronal loss due to the direct toxicity of lacta-
cystin, including the red nucleus, immediately
supranigral to the SNc and in numerous nuclei in the
VM adjacent to the needle injection tract. These data
are illustrated by representative photomicrographs in
Figure 5C and 5D.
Consistent with loss of nigral TH/NeuN+ cell bodies,
densitometry analysis revealed a 69.6 ± 2.5% reduction
of TH+ fibre density in the ipsilateral striatum, relative
to the non-injected contralateral striatum of lactacystin-
lesioned animals (61.29 ± 1.99 vs. 18.61 ± 1.54; p <
0.001; Figure 5E, F) confirming significant loss of DA
axon terminals. No significant differences were observed
in TH+ fibre optical density in the contralateral striatum
when comparing lactacystin-lesioned animals and saline
controls, or between the contralateral and ipsilateral
striatum in saline-injecteda n i m a l s( F i g u r e5 E ,F ) .
Figure 2 (A) Representative T2W MR images from saline-injected control subject with sample ROIs utilised for quantitative volumetric
analysis of individual brain regions. (B-G) Bar graphs of regional brain volumetric data measured on in vivo T2W anatomical MRI scans
acquired from saline and lactacystin-injected animals 3 weeks post-lesion. (B) Whole brain volume, (C) corpus striatum, (D) ventral midbrain, (E)
lateral ventricles, (F) cerebellum and (G) hippocampal formation. Data are expressed as mean volume mm
3 ± s.e.m. *p < 0.05, **p < 0.01;
ipsilateral vs. contralateral hemisphere; *p < 0.01; ipsilateral hemisphere of lactacystin vs. saline-injected; §p < 0.05 contralateral hemisphere of
saline vs. lactacystin-injected.
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either NeuN+ or DARPP-32+ cells in the ipsilateral
striatum of lactacystin-lesioned animals, suggesting g-
amino-butyric-acid (GABA-ergic) medium spiny neu-
rons in the STR may be preserved (Figure 6A,B).
In the SNc of lactacystin-lesioned animals, aggregation
of a-synuclein was observed, compared to the diffuse
staining in the SNc of control animals (Figure 7A-D).
Pre-treatment with proteinase K allowed selective visua-
lisation of insoluble a-synuclein deposits and abolished
immunostaining for endogenous soluble a-synuclein.
This revealed focal cytoplasmic proteinase-K resistant
a-synuclein immunoreactive inclusions in a small pro-
portion of cells in the SNc of lactacystin-lesioned ani-
mals, which were not present in saline controls (Figure
7E, F).
Prussian blue (PB) histology revealed minimal iron
deposits in the striatum of both lactacystin and saline-
injected animals (Figure 8A). By contrast, PB histology
revealed clear and extensive iron accumulation in the
ipsilateral SNc of lactacystin-lesioned animals compared
to saline controls (Figure 8B). In support of this, densi-
tometry analysis exposed a significant increase in iron
accumulation in the ipsilateral SNc of lactacystin
lesioned animals compared to saline controls (Figure
8C). Iron deposits were, however, also observed in the
SNr and in extra-nigral nuclei in the ventral midbrain,
near to the injection tract, as well as in the contralateral
hemisphere of lesioned animals compared to saline con-
trols. (Figure 8B, D).
Relationships between in vivo MRI, behaviour and post-
mortem histology
To determine whether in vivo MRI measurements are
linked to behavioural and histological outcomes in this
model, we correlated MRI- measurements with beha-
vioural impairments and histological measures of nigros-
triatal damage in this model (Tables 2 and 3,
respectively). Significant negative correlations were
found between apomorphine rotation and WBV, ipsilat-
eral STR and VM volumes (Table 2), whilst LV hyper-
trophy correlated positively with apomorphine rotations.
By contrast, only ipsilateral STR volume was
Figure 3 Representative T2W MR images through the striatum (panel A) and midbrain containing the substantia nigra (SN; panel B)
to illustrate regional brain atrophy in saline and lactacystin-injected animals. Clear hypertrophy of both the ipsilateral (solid arrows, A) and
contralateral (dashed arrows, A) LV can be observed in lactacystin-lesioned animals, compared to saline controls. In the midbrain (panel B) the
sub-cortical area containing the SN in the ipsilateral hemisphere appears clearly deformed compared to the intact contralateral hemisphere (solid
arrows). Note also the increased CSF signal, suggestive of a volume change in this region. In addition, areas of T2 hypointensity are observed in
the SN, but also in extra-nigral nuclei (dashed arrows).
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Page 6 of 18Figure 4 Bar graphs of T2 relaxivity measured from parametric T2 maps generated from T2W MRI scans acquired 3 weeks post-lesion
from saline and lactacystin-injected animals. (A) No significant difference in T2 was observed in the striatum between saline and lactacystin-
injected animals. By contrast, moderate, but significant reductions in T2 were observed in the ventral midbrain (C) and substantia nigra (E) of
lactacystin-injected animals compared to saline controls. Example ROIs used to generate quantitative T2 data are shown for striatum in (B),
ventral midbrain (D) and substantia nigra (F), respectively. Data shown are the ratio of T2 between the contralateral and ipsilateral hemispheres ±
SEM for saline and lactacystin-injected animals, respectively. *p < 0.05; saline vs. lactacystin.
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Page 7 of 18Figure 5 Histological assessment of nigrostriatal integrity 3 weeks post-lesion. Quantification by unbiased stereology revealed intranigral
injection of lactacystin resulted in a marked decrease in (A) the number of TH+ cell bodies in the ipsilateral SNc, mirrored by a clear reduction
in (B) NeuN+ cells. ***p < 0.001; contralateral vs. ipsilateral hemisphere, #p < 0.01; ipsilateral hemisphere of lactacystin vs. saline controls. (C, D)
Representative photomicrographs of TH+ staining in saline and lactacystin-lesioned animals. Note the extensive loss of TH+ and NeuN+ cells in
the ipsilateral SNc, but also in the VTA, SNr and extranigral nuclei in proximity to the injection tract of lactacystin-injected animals (arrows)
(Magnification (C) × 1.5, scale bars 500 μm; (D) ×4, scale bars 200 μm). Concomitant with nigral cell body degeneration, a substantial
dennervation of TH+ fibres was observed in the ipsilateral striatum of lactacystin-lesioned animals quantified by optical densitometry (E) and
illustrated by a representative photomicrographs in (F) (magnification ×1.5, scale bar 500 μm; insets ×40, scale bar 20 μm). ***p < 0.001;
contralateral vs. ipsilateral hemisphere, #p < 0.01; ipsilateral hemisphere of lactacystin vs. saline controls.
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limb grip strength. No significant relationships were
observed between either cerebellar volume or hippocam-
pal volume and any behavioural measure. In addition,
significant associations were found between the number
of TH+ and NeuN+ cells in the ipsilateral SNc with
changes in WBV, ipsilateral VM and STR volume. Inter-
estingly, a significant relationship was found between
TH+ fibre density and ipsilateral STR volume. In addi-
tion, these histological measures all correlated robustly
with LV hypertrophy. There was no significant link
between any histological measure and HF or CB volume.
No significant associations could be found between
ipsilateral SN T2 values any behavioural measure at 3
weeks post-lesion (Table 3). In addition, no significant
associations could be found between SN T2 values and
the number of surviving TH+ and NeuN+ cells in the
SN, or the density of TH+ fibres in the striatum. How-
ever, a significant relationship could be observed
between the degree of iron accumulation and T2 values
in the SN (r = -.793; p < 0.01). No significant relation-
ships between striatal T2 values and behavioural or his-
tological outcomes were observed. For completeness, ex
vivo post-mortem histological measures were also
Figure 6 Lactacystin lesioning does not result in loss of striatal medium spiny neurons. (A) Whole brain photomicrogaphs of NeuN and
DARPP-32+ cells in the striatum of saline and lactacystin lesioned animals (×1.5 magnification, scale bar = 500 μm). (B) Higher magnification of
NeuN+ and DARPP-32+ cells in the striatum of saline and lactacystin injected animals, respectively. (×40 magnification, scale bar = 20 μm). Note
the enlarged ventricles in lactacystin-injected animals (asterisks in A).
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Page 9 of 18correlated with behavioural outcomes in this model. As
expected, there were strong correlations with the num-
ber of TH+ cells in the ipsilateral SNc and both apo-
morphine rotations (r =- . 9 4 7 ;p < 0.01) and forelimb
grip strength (r = .732; p < 0.05). The number of NeuN
+ cells in the ipsilateral SNc also strongly correlated
with both apomorphine rotations (r =- . 8 8 2 ;p < 0.01)
and forelimb grip strength (r = .829; p < 0.05). Similarly,
highly significant relationships were observed between
TH+ cell number and NeuN+ cell number in the ipsilat-
eral SNc (r = .932; p < 0.01) and TH+ fibre density in
the striatum (r = .943; p < 0.01).
Discussion
Using in vivo T2-weighted (T2W) MRI, we have been
able to detect for the first time a pattern of morphologi-
cal changes in the brains of rodents bearing a unilateral
lesion of the nigrostriatal system induced by intranigral
Figure 7 (A-D) a-synuclein immunohistochemistry reveals the presence of soluble aggregates of a-synuclein in the substantia nigra of
lactacystin-lesioned animals compared to saline controls (panels A, B: ×4 magnification, scale bars = 200 μm; panels C, D: ×40
magnification, scale bars = 20 μm). Note the diffuse pattern of staining in control animals compared to the punctate labelling observed in
lactacystin-lesioned animals, indicative of aggregation. (E-F) Pre-treatment with proteinase K (10 μg) reveals the presence of insoluble perinuclear
a-synuclein aggregates in the SNc of lactacystin-injected animals, but not saline controls (×60 magnification, scale bars = 10 μm).
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moderate, but significant global reduction in brain
volume, accompanied by a striking deformation of the
ipsilateral VM, shrinkage of the ipsilateral striatum and
hypertrophy of the LV. Although the presence of BG
atrophy in PD patients is a matter of controversy [6,7]
these data correspond robustly with recent published
data from clinical neuroimaging studies in iPD patients.
Indeed, morphological changes, including decreased
striatal volume and LV hypertrophy have been reported
[4,10-12]. Nevertheless, midbrain atrophy is commonly
detected in MRI from patients with atypical PD, such as
MSA or PSP [13,14]. No changes were observed in
either cerebellar or hippocampal volume. We further
observed a slight, but significant decrease in T2 relaxiv-
ity in the SN, consistent with previous reports of this
Figure 8 (A) Prussian blue and cresyl violet histology reveals no apparent iron accumulation in the striatum of both saline and
lactacystin-lesioned animals (arrowheads in A) (×2.5 magnification, scale bars = 300 μm; insets × 40 magnification, scale bars = 20
μm). (B) By contrast, extensive iron deposits are observed in the SNc of lactacystin lesioned animals but not saline controls (arrowheads in B);
(×2.5 magnification, scale bars = 300 μm; insets ×40 magnification, scale bars = 20 μm). Note that iron deposition is not confined to the SN but
is also present in extra-nigral regions (C) Densitometry measurements confirmed the increased in iron deposition in the SN of lactacystin-
lesioned animals compared to saline controls. Data shown are mean optical density values (arbitrary units) ± SEM. **p < 0.01; saline vs.
lactacystin. (D) Iron deposits were also observed in proximity to the needle-tract of lactacystin-lesioned animals, but not saline controls (arrowsi n
D) (×2.5 magnification, scale bar = 300 μm). Interestingly, iron accumulation appears to overlap with areas of neuronal loss in the midbrain of
lactacystin-lesioned animals as shown in Figure 5D.
Table 2 Two-tailed Pearson correlations for all subjects between specific brain region volumes derived from MRI
measurements, behavioural deficits and histological measurements.
Regional MRI volume Apomorphine rotations Forelimb grip strength TH+ cells NeuN+ cells TH+ fibres
WBV -.767** .420 .832* .718* . 821**
VM -.955** .599 .980** .868** .861**
STR -.746** .666* .798* .868** .715**
LV .811** -.467 -.775* -.730* -.713*
HPC .489 -.211 -.496 -.312 -.398
CB .025 -.339 .081 -.083 .034
*p < 0.05, **p < 0.01.
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could not find any change in T2 in the STR in this
model. In addition to these MRI signal changes, lacta-
cystin-lesioned animals displayed robust parkinsonian-
like behavioural defects and classical nigrostriatal
pathology, including a-synuclein aggregation in the SN,
consistent with previous reports describing the develop-
ment of this rodent pre-clinical model [34-36].
Relationship between morphological changes detected by
MRI with behavioural and histological outcomes
Examination of the relationship between MRI signal
changes and behavioural outcomes revealed that volu-
metric changes in the ipsilateral VM, striatum and LV
were significantly correlated to apomorphine rotation,
whilst only ipsilateral striatal volume was significantly
associated with impaired grip strength in this model.
These data suggest volumetric MRI measurements of
these areas could be predictive of the degree of some,
but not all, functional impairments in this model, con-
sistent with human studies [4,12]. These preliminary
data, albeit in a small number of subjects, raise the pos-
sibility that these volumetric in vivo MRI measures may
be useful surrogate markers of disease progression in
this model. In addition, previous studies have demon-
strated that lactacystin-lesioned animals also show sig-
nificantly impaired performance in the accelerating
rotarod test and overall locomotor activity [36]. Thus it
may be interesting in future studies to additionally
examine the relationship between MRI volumetric
changes and performance in these motor tasks in lacta-
cystin-lesioned animals, which may provide further evi-
dence for MRI volumetric changes in this model as
surrogate markers of nigrostriatal dysfunction. Impor-
tantly, however, repetition of this analysis in a larger
group of subjects and comparison to established pre-
clinical models of PD (6-OHDA/MPTP) are required to
fully establish the reliability and specificity of these sur-
rogate markers.
In addition, post-mortem validation of MRI signal
changes is crucial before these can be accepted as surro-
gate markers of disease progression. An important corol-
lary to this is that lactacystin can induce both selective
damage to DA neurons or more widespread cell loss.
Indeed, in vitro, lactacystin has been reported to induce a
significant loss of only DA neurons [39] or both DA and
GABAergic neurons [40,41]. In contrast, in vivo, intrastria-
tal injection of lactacystin (10 μg) induced a general
neuronal toxicity in the striatum [42]. Importantly, in the
current study, volume decreases were significantly corre-
lated with the number of surviving TH+ and NeuN+ cell
numbers in the ipsilateral SN, but also the density of TH+
fibres in the ipsilateral striatum. However, lactacystin not
only induced neuronal loss in the pars compacta and pars
reticulata of the SN, but also in the VTA, a nucleus that is
relatively preserved in human iPD [1]. Thus, whilst the
morphological MRI changes observed in the current study
are certainly linked to a specific loss of A9 DA neurons, at
least in part, we cannot exclude the possibility that these
are also due to an additional loss of other vulnerable neu-
ronal populations.
Additionally, focal areas of neuronal loss were
observed throughout the ipsilateral VM along the needle
injection tract, consistent with previous reports [42].
This phenomenon most likely explains the extensive
deformation of the ipsilateral VM observed on the MRI
scans. Thus, although volumetric MRI measures were
strongly associated with both behavioural and ex vivo
histological measures, their use as surrogate markers of
nigrostriatal damage might be limited, since volumetric
changes in these regions do not discriminate between
damage to the nigrostriatal or other neuronal popula-
tions in the midbrain in this model.
Although TH+ fibre density was dramatically reduced
in the ipsilateral striatum of lactacystin-lesioned animals,
qualitatively, no gross loss of either NeuN+ or DARPP-
32+ cells was apparent. Thus, striatal medium spiny
neurons (MSN) appear to be preserved in this model.
Interestingly, TH+ fibre loss and dopamine depletion
are reported to be associated with synaptic remodelling
and dendritic changes in striatal MSN in 6-OHDA
lesioned rodents [43,44]. These data are consistent with
reports of decreased MSN dendrite spine number and
length in the striatum of post-mortem PD brains [45].
Conceivably therefore, decreased striatal volume could
be attributed to TH+ fibre loss and subsequent dendritic
remodelling. It is tempting to speculate therefore that
striatal volumetric change may be a conserved marker
of nigrostriatal degeneration across pre-clinical models
of PD and perhaps human iPD, which importantly, cor-
relates with behavioural and clinical outcomes [4]. How-
ever, investigation of volumetric MR changes in
established PD models that induce selective nigrostriatal
DA cell death, such as 6-OHDA or MPTP, will be
important to validate this hypothesis.
Table 3 Two-tailed Pearson correlations for all subjects between MRI volume measurements of individual brain
regions and whole brain volume. *p < 0.05, **p < 0.01.
T2 signal intensity Apomorphine rotations Forelimb grip strength TH+ cells NeuN+ cells TH+ fibres
SN -.158 .405 .467 .159 .452
STR -.044 -.076 .327 -.341 -.240
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MRI with behavioural and histological outcomes
In contrast to our findings, previous studies have identi-
fied increased T2 relaxation times, visualised as areas of
signal hyperintensity on T2W MR images in both 6-
OHDA-lesioned rodents [27] and MPTP-treated pri-
mates [28]. Importantly, these findings were reported at
acute time-points post-lesion (24 hrs to 7 days) and T2
hyperintense areas were observed to dissipate on subse-
quent MRI scans with increasing time post-lesion
[27,28]. It is therefore possible that T2 relaxation may
evolve with time, although this may not be a reflection
of a continuous physiological phenomenon. Indeed,
increases in T2 at acute stages post-lesion most likely
reflect acute oedema [27]. By contrast, at longer time-
points post-lesion, iron accumulation appears to be the
primary cause of T2 signal decrease, as suggested by our
findings and those of others [30,46]. Importantly,
although previous studies have suggested a link between
changes in SN T2 relaxation time and nigral cell death
[27], this has not been robustly established in vivo.W e ,
for instance, could not find a significant relationship
between ipsilateral SN T2 values and either TH+ or
NeuN+ cell number in the SNc. Although the number
of subjects in our study was small, these data are in
agreement with recently published findings in MPTP-
treated primates [30]. One plausible explanation of these
findings may be related to iron accumulation in the SN.
Iron deposition is known to affect MR signal intensity
by creating magnetic field inhomogeneities that de-
phase nearby water-protons leading to shortening of T2
relaxation time and signal drop off in the affected tis-
sues [47]. In support of this, we observed substantial
iron accumulation in the ipsilateral SN of lactacystin-
lesioned animals, but not saline controls. Furthermore,
we observed a significant relationship between T2 and
iron accumulation as measured by Prussian blue histol-
ogy in the SN 3-weeks post-lesion. These data are in
good agreement with the findings of Zhu and colleagues
(2007) who initially reported the observation of signifi-
cant iron accumulation in the SN in this model by bio-
chemical measurement of iron content in the SN [36].
Interestingly, previous studies have shown that treat-
ment with novel iron chelators prevented nigral iron
accumulation and protected the nigrostriatal system
against lactacystin-induced neurodegeneration in vivo
[35,36]. Speculatively therefore, in vivo MR measure-
ment of nigral T2 values may be a potentially useful sur-
rogate measure of the neuroprotective efficacy of novel
iron chelators in this rodent model of PD, which may
warrant further investigation in vivo.
Overall, these data are also consistent with MRI find-
ings in PD patients reporting decreased T2 relaxation
time in the SN [15-18] and biochemical measurements
reporting increased iron accumulation in the SN of PD
patients [48,49]. Interestingly, changes in SN T2 relaxa-
tion in PD patients appear to correlate with some clini-
cal symptoms, although the exact relationship is unclear
[19,20]. Based on these clinical reports, it has been sug-
gested that T2 signal changes may be a useful surrogate
marker of PD progression [19,20]. Importantly, in this
PD model at 3 weeks post-lesion, ipsilateral SN T2
relaxivity was not significantly associated with any beha-
vioural outcome in this cross-sectional study.
Taken together, it may be suggested that at least two
distinct physiological processes underlie changes in
nigral T2, which evolve over time and may in part coun-
terbalance each other. Clearly therefore, longitudinal
studies are required to further elucidate the relationship
between changes in T2 and behavioural or histological
outcomes in this model to determine whether this can
be a useful surrogate marker of ongoing nigrostriatal
degeneration in vivo.
It is also noteworthy, however, that in lactacystin
lesioned animals we observed numerous areas of T2
hypointensity on our T2W MR images throughout the
midbrain and not only in the SN. This finding is incon-
sistent with the patterns of either iron deposition
[48,49] or T2 relaxivity changes detected by MRI in PD
patients [19,20]. This was reflected in both quantitative
T2 measurements and post-mortem histology, where
clear areas of iron accumulation could be observed not
only in the SNc, but also the SNr as well as in areas sur-
rounding the needle tract, where ongoing neuronal loss
was also evident.
Conclusions
In summary, this study has identified a pattern of mor-
phological changes in lactacystin lesioned animals, as
well as alterations in nigral T2 relaxivity, that are some-
what consistent with published clinical neuroimaging
data from iPD patients. Interestingly, morphological, but
not T2 relaxivity changes, were associated with both
behavioural and histological outcomes in this model.
This raises the possibility that morphological changes
may be non-invasive surrogate markers of nigrostriatal
degeneration in vivo in this pre-clinical model. However,
post-mortem immunohistological analysis revealed that
lactacystin induced non-specific neuronal loss in the
VM, as well as widespread iron accumulation. Taken
together, these data suggest that MRI signal changes in
this PD model are not wholly specific to degeneration of
the nigrostriatal system alone, potentially limiting the
usefulness of these markers. Nevertheless, this model
has pathological relevance to human iPD, and may be a
useful tool to study the relationship between proteasome
dysfunction, abnormal accumulation of a-synuclein and
DA neurodegeneration in vivo. Moreover, these data
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tion of pathological changes in the brain in pre-clinical
models of neurodegenerative disease.
Methods
Experimental animals
Male Sprague-Dawley rats (250 ± 10 g, Harlan, UK)
were housed in groups of three at 21 ± 1°C on a 12 hr
light: dark cycle (lights on 0700, lights off 1900). Stan-
dard rat chow and drinking water were available ad
libitum. All animal experiments were carried out with
local ethical approval and in accordance with the
Home Office Animals (Scientific procedures) Act, UK,
1986.
Animals were randomised to either saline or lesion
groups (n = 6 per group) and anaesthetised by i.p.
injection of a mixture of medetomidine hydrochloride
(Domitor®, 0.25 mg/kg) and ketamine hydrochloride
(Vetalar™, 230 mg/kg) in sterile water and positioned
in a stereotaxic frame (Kopf Instruments, Tujunga, CA,
USA) with the incisor bar set 3.3 mm below the inter-
aural line. Nigrostriatal lesions were induced by a uni-
lateral intranigral injection of the proteasome inhibitor
lactacystin (10 μgi n2 . 5μl; L6785, Sigma-Aldrich,
Poole, UK) at the following stereotaxic co-ordinates,
AP: -5.2 mm, ML: +2.4 mm lateral from bregma and
-7.6 mm ventral to dura [50] as previously described
[34]. Lactacystin was dissolved in 0.9% saline (pH 7.4)
immediately prior to use and stored on ice to prevent
degradation. Injections were performed at a rate of 1
μl/min using a motorized syringe pump and the needle
was slowly withdrawn 5 min after lesioning to mini-
mize diffusion of toxin into the injection tract.
Anesthesia was reversed 1 hr after induction by subcu-
taneous (s.c.) injection of atipamezole hydrochloride
(Antisedan®, 5 mg/kg). Sham-lesioned animals under-
went identical surgery, but received an injection of
0.9% saline. Saline and lactacystin groups were oper-
ated on in a randomised fashion in the same surgical
session. Post-operative care included analgesia
(buphrenorphine, 0.3 mg/kg s.c. during the first 48 hr),
fluid-replacement (4 ml glucosaline solution i.p.) and
mashed high-nutrient food pellets during the first
week after surgery. Animals were weighed and semi-
quantitatively scored daily for neurological deficits
using a general neurological rating scale as previously
described [51]. This was done daily in a blinded fash-
ion until the end of the experiment.
Behavioural testing
Animals were routinely handled prior to and after sur-
gery in order to calm the animals and enhance reliability
when testing. Prior to any behavioural testing (training
or trial) animals were allowed to acclimatize to the test-
ing room for 30 min.
Grip strength meter test
To investigate forelimb motor dysfunction following lac-
tacystin-lesioning performance in the grip strength test
was assessed using a grip strength meter (GSM; TSE
Systems, Bad Homberg, GER) as previously described
[52]. Briefly, forelimb grip strength was tested in ses-
sions consisting of five trials separated by approx. 1
min. Animals underwent training prior to surgery to
familiarise themselves with the GSM apparatus. This
consisted of one day of testing for five trials, per paw,
per animal. Subsequent test sessions were conducted
preoperatively to establish a baseline, with subsequent
re-testing 3 weeks post-surgery. Test sessions were per-
formed on one day both in the morning and afternoon,
as per training with 5 trials per paw, per animal. The
mean force exerted on the GSM by each forepaw just
prior to grip release was recorded automatically per paw
(contralateral and ipsilateral to the lesion) for each ani-
mal by a strain gauge connected to a digital readout. An
average grip force was then calculated for each limb, for
all animals in each group.
Rotational asymmetry
Three weeks post-lesion, drug-induced rotation as an
index of nigrostriatal damage was evaluated in a bank of
eight rotameter bowls. Lesioned and control animals
were harnessed into jackets tethered to an automated
rotameter and allowed to acclimatize for 30 min before
administration of apomorphine hydrochloride (0.1 mg/kg
dissolved in 0.9% saline, s.c., Sigma-Aldrich, Poole, UK).
The numbers of complete contraversive rotations were
then measured over 60 minutes using an automated rota-
meter (TSE Systems, Bad Homberg, Germany).
Magnetic resonance imaging
Preparation
Animals underwent MRI imaging 3 weeks post-surgery,
after completion of behavioural testing, based on pre-
vious behavioural and histological studies of nigrostriatal
damage in this model [34]. Animals were anesthetized
using isoflurane (5% induction, 1.5% maintenance) in an
oxygen/medical air (30%: 70%) mixture delivered at 1 L/
min and placed in a PTFE MRI compatible stereotaxic
head frame to reduce head movement. Body tempera-
ture, respiration rate, blood oxygen saturation and pulse
rate were monitored for the duration of the scan. Ani-
mal body temperature was maintained at 37°C using a
heated blanket.
Image acquisition
T2W MR images were acquired using a 7.0 T horizontal
small bore magnet (Varian, Palo Alto, CA, USA) and a
custom built head RF coil (David Herlihy) linked to a
LINUX-based control console running VnmrJ acquisi-
tion software (v2.3, Varian, Palo Alto CA, USA). T2W
images were acquired using a multi-echo, multi-slice
spin-echo pulse sequence (MEMS), with the following
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× 192; TR = 4200 ms; TE = 10, 20, 30, 40, 50, 60, 70, 80
ms; 4 averages, scan duration 54 minutes. Fifty contigu-
ous 500 μm-thick coronal slices with an in plane resolu-
tion of 189 × 189 μm were acquired such that the entire
brain of each animal was covered. Once scanning was
completed, animals were removed from the magnet bore
to a separate holding room, administered 4 ml 0.9% sal-
ine solution (i.p.) and placed in a heated recovery cham-
ber. Following full recovery from anaesthesia, animals
were then returned to their home cages.
Image post-processing
Brain images were transferred from the console to a
workstation, where they were visually inspected prior to
post-processing for motion or intensity artefacts. No
scans were excluded on this basis. Images were interpo-
lated from the acquired 192 × 192 matrix corresponding
to a 189 μm in-plane linear pixel size to a 256 × 256
pixel grid (136 μm voxel size). For quantitative manual
volumetric measurements, images corresponding to TE
= 10-80 ms were summed and converted to Analyse 7.5
(Mayo Clinic). Quantitative T2 relaxation maps were
also obtained by a mono-exponential fit of the eight
multi-echo images (TE = 10-80 ms) using VnmrJ
software.
MR image analysis
For whole brain and regional volumetric analysis, struc-
tures were delineated manually. Individual brain struc-
tures were delineated by a single reviewer (A.C.V)
blinded to animal surgical status on a slice-by-slice basis
in the coronal plane using the ROI tool in JIM v5.0 soft-
ware (Xinapse systems, Thorpe Waterville, UK). ROIs
were traced in both the ipsilateral and contralateral
hemispheres of sham and lesioned animals at low mag-
nification followed by manual correction of borders at
higher magnification. Clear anatomical landmarks and
reference to the standard rodent brain atlas [50] were
used to define ROIs for each region analysed in each
slice (Table 1). Volumes were calculated by multiplying
the sum of the areas of a given structure on all slices by
the slice thickness for each animal. Intra-rater-reliability
was assessed following repeated measurements using the
intra-class-correlation coefficient (ICC). For all brain
regions examined, an ICC value of ≥ 0.9 was obtained,
suggesting robustly reliable segmentation of brain
structures.
Intensity values for T2 were measured in both the
contralateral and ipsilateral hemispheres of saline and
lactacystin-lesioned animals in the striatum, ventral mid-
brain and the SN from quantitative T2 maps using
VnmrJ software. To measure T2, an ROI was drawn
using the ROI tool in VnmrJ on a representative coronal
slice, examples of which are shown for each brain region
analysed in Figure 4B,D and 4F. A rodent brain atlas
[50] was used to interpret the MR images and define
ROI borders. For the SN, atlas plates containing the SN
were overlaid onto MR images to aid identification of
this structure. No difference could be made between the
pars reticulata and the pars compacta of the SN thus T2
measurements in this area refer to the whole SN. Values
for T2 are expressed as the ratio between the contralat-
eral and ipsilateral striatum and SN (relative T2).
Tissue collection
One day post-imaging, animals were terminally anaes-
thetised by a sodium pentobarbital overdose (60 mg/kg
i.p.) and transcardially perfused first with 0.9% saline,
followed by ice-cold 4% paraformaldehyde (PFA) in 0.2
M phosphate buffer, pH 7.4. Brains were rapidly dis-
sected out, post-fixed for 24 hours and cryo-protected
in buffered 30% sucrose. Serial coronal sections (40 μm)
were cut on a freezing microtome at -20°C and stored
in cryoprotective solution containing 0.05% sodium
azide at -20°C until processed for
immunohistochemistry.
Immunohistochemistry
Free-floating sections were immunostained with the fol-
lowing primary antibodies, rabbit a-tyrosine hydroxylase
(TH, AB151, Chemicon, 1:3000), mouse a-Neuron spe-
cific nuclear protein (NeuN, MAB377, Chemicon,
1:1000), mouse anti-a-synuclein (610786, BD Bios-
ciences, 1:100) and rabbit a-dopamine and cAMP-regu-
lated phosphoprotein-32 (DARPP-32; AB1656;
Chemicon, 1:1000) using a standard immunoperoxidase
method as described elsewhere [53].
Briefly, sections were rinsed with PBS, then incubated
for 10 min in 0.3% H2O2 (Sigma-Aldrich) to quench
endogenous peroxidase activity. For a-synuclein immu-
nohistochemistry, sections were then incubated with or
without PBS containing 10 μg/ml proteinase K (Pro-
mega, Southampton, UK) for 10 min at room tempera-
ture, to visualise both soluble and insoluble a-synuclein.
Non-specific binding was blocked by incubation for 1 hr
in blocking solution containing 10% normal sera and
0.03% triton X-100 diluted in PBS. All antibodies were
diluted in blocking solution and sections were thor-
oughly washed in PBS between each step. Tissue sec-
tions were incubated with primary antibodies at 4°C
overnight, followed by 2 hr incubation at room tempera-
ture (RT) with secondary biotinylated anti-mouse anti-
bodies (1:200, Vector Laboratories) and a further 1 hr
incubation at RT with an avidin-biotinylated-peroxidase
complex (Vectastain ABC kit, 1:100 in PBS, Vector
Laboratories). The substrate 3,3’-diaminobenzidine
(DAB Fast tablets, Sigma-Aldrich, dissolved in dH2O
with the addition of H2O2 to a concentration of 0.03%
immediately before use) was used as chromagen. Anti-
body specificity was confirmed in adjacent tissue sec-
tions with the primary or secondary antibody omitted.
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for iron accumulation using Pearl Prussian blue staining
as described elsewhere [46]. Finally, sections were
washed in PBS, counterstained with cresyl fast violet
(CFV) and mounted onto glass slides, dehydrated in
graded alcohol and xylene before being coverslipped
with DPX (Merck, Lutterworth, UK).
Unbiased stereology cell counts of nigral dopaminergic
neurons
To estimate the remaining number of TH-positive (TH
+) neurons within the SN in sham and lactacystin-
lesioned animals, cell counts were performed using an
unbiased stereological three-level fractionator sampling
method on a computerized image analysis set-up (Zeiss
Axioscope, Carl Zeiss, Gottingen, GER) running Stereo
investigator software (v7.0, MBF Bioscience, Chicago, IL,
USA). Every 6
th section throughout the rostro-caudal
extent of the SN was systematically sampled using an
unbiased counting frame (the “optical fractionator”)o f
known area superimposed on the field of view by the
software. In each tissue section analyzed, section thick-
ness was assessed empirically and guard zones of 2 μm
thickness were used at the top and bottom of each sec-
tion. The SN was manually outlined at ×2.5 magnifica-
tion and counting frames were systematically distributed
with known x and y steps throughout the region from a
random starting point. At least 20 counting frames were
sampled per section. All cell counts were performed
under ×40 magnifications. The coefficients of error (CE)
were calculated according to the procedure of West and
colleagues with values <0.10 accepted [54]. To ensure
the absence of bias in cell counting, slides were coded
such that the operator was blinded to the surgical status
of the animal. To establish that changes in TH+ cells
reflected cell death and not reduced expression of TH
protein, additional cell counts were performed in paral-
lel for NeuN-positive (NeuN+) cells in the SN as
described above.
Optical density measurements
Optical density of TH+ fibres in the corpus striatum
was measured as previously described with modification
[55]. Briefly, digital images of TH-stained sections were
captured in a blinded fashion from coded slides across 8
different rostral to caudal levels of the striatum (+1.5 to
-2.0 mm AP relative to bregma) at ×2.5 magnification
using a Zeiss Axioscope microscope. At each level, for
both the ipsilateral and contralateral hemispheres of the
brain, images were manually thresholded to highlight
TH-staining in the striatum. The area containing the
striatum in each section was then traced manually and
optical density automatically calculated using the area
f r a c t i o nt o o li nI m a g e Js o f t w a r e( N I H ,h t t p : / / r s b . i n f o .
nih.gov/ij/). Non-specific background densities were
measured in the corpus callosum (an area devoid of TH
staining) and subtracted to give corrected striatal optical
density values. This method was also applied to quantify
t h ed e g r e eo fi r o nd e p o s i t i o ni nt h eS N .B r i e f l y ,d i g i t a l
images of tissue sections stained with Prussian blue and
nissl stain were captured from coded slides at × 40 mag-
nifications using a Zeiss Axioscope microscope. The
optical density of Prussian blue stained cells was quanti-
fied as outlined above, from 3-5 sections per subject in
each group.
Statistical analysis
All data are expressed as the mean ± SEM. Net contra-
versive turns for lactacystin or saline-injected treated
animals in response to apomorphine hydrochloride were
plotted against time and the area under the curve
(AUC) calculated in Graphpad Prism (v4.0 San Diego,
CA, USA). The resultant means of AUC ± SEM for lac-
tacystin or saline-injected animals were then compared
u s i n gt w o - t a i l e dp a i r e ds t u d e n t ’st - t e s t .G r i ps t r e n g t h
data, MR regional volumes, quantitative T2 measure-
ments and histological data were analysed using stan-
dard paired two-tailed student t-tests to compare
differences within groups and unpaired two-tailed t-tests
to compare differences between groups in Graphpad
Prism. Correlations between regional brain volume
changes, histology and motor behaviour were calculated
for all subjects (both saline controls and lactacystin-
lesioned animals) using a two-tailed Pearson correlation
analysis in SPSS (v16.0, Woking, UK). In all cases, statis-
tical significance was set at p < 0.05.
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